Conflicts of Interest Summary, plagiarized by the Lyme Disease Association.

LDA’s plagiarized COI report (“Pat’s Big Books”) http://module.lymediseaseassociation.org/ConflictReport.pdf
Now you know she knows about the RICO and also that OspA alone caused the same disease.
170812_LDA_PLAIGIARISM
https://groups.google.com/forum/?hl=en#!original/sci.med.diseases.lyme/Lhb_gDy9UOw/PCcId4NI_JoJ

From: Kathleen <kathleen...@snet.net>
Subject: Re: Steere and NIH: A real life tragedy e-petition Part II
Date: 1999/10/25
Message-ID: <3814E2E6.1F0E@snet.net>
X-Deja-AN: 540542971
Content-Transfer-Encoding: quoted-printable
References: <3812663F.E73ABC3B@jersey.net> <6gGQ3.13773$2T2.80569@news.rdc1.nj.home.com>
Content-Type: text/plain; charset=iso-8859-1
Organization: Lyme
Mime-Version: 1.0
Reply-To: kathleen...@snet.net
Newsgroups: sci.med.diseases.lyme

e-Petition to the U.S Government to stop funding University-based =20
Rheumatologists, Immunologists, and other researchers (UBRs) whose=20
endeavors have taken them away from the study of TREATMENT modalities=20
for Lyme disease and instead leads them to the profitability in=20
DIAGNOSTICS and PREVENTION: =20

We contend that we immediately need a CURE, and that the US Govt=20
should stop funding UBRs whose endeavors we will describe.

  Recently some of these UBRS in New York have initiated an=20
attempt to have licenses revoked of some Lyme-Literate Physicians=20
(LLMDs -Those who understand the disease and try to help the=20
patients recover) in New York. This presents a problem because=20
there are few in the northeast, as elsewehere,  who have the=20
courage to face the harrassment of these SUNY-based UBRs, as well=20
as insurance companies, in order to treat Lyme disease patients. These=20
Lyme-Literate Physicians, the ones criticized by these highly funded
researchers, are the ones who have the experience and expertise that=20
reflects the state of current knowledge of treatment.
  We herein point out that the efforts and focus of these highly=20
funded UBRs' is in discovering molecules of interest to vaccine=20
manufacturers and for sale in diagnostic test kits.  The evidence=20
follows. We contend that A. Barbour, R. Dattwyler, B. Luft, L. Sigal,=20
E. Fikrig and Allen Steere, R. Schoen, J. Evans and others who claim
Lyme is Overdiagnosed and Overtreated; the self-proclaimed experts=20
who are getting most of the funding regarding Lyme disease, are=20
interested in the commercial value of this disease and not in curing=20
patients. We seek a review of the results of government (NIH, CDC)=20
funding to these UBRs who seek molecules and diagnostic methods to=20
patent for profit, as we question the ethics and legality of such=20
endeavors.
  Many of the above group of people (UBRs) claim Lyme disease becomes an=20
autoimmune disease for which antibiotics do not cure, and/or from=20
whom a diagnosis of NOT LYME benefits insurance companies and is=20
more profitable, per-patient-minute, than treating Lyme disease=20
patients.  There is no proof yet of Lyme causing an autoimmune
disease. =20
------Patents and Grants  $$$$$$$$
__Alan Barbour (of the ALDF)___ Barbour owns a patent for a rOSP A=20
(one of the two vaccines for Lyme) and then some.  Alan Barbour had=20
this to say about Claire Fraser's publication of a Borrelia=20
burgdorferi genome  in Nature Dec 1997:
"...But those who expecting to find in B.b. a rich vein of gold in which
to mine virulence determinants have to be disappointed.....The results=20
encourage study of a more metabolically competent spirochete, such as
the=20
Spirocheta aurentia, for a better understanding of how this ancient=20
group of bacteria evolved, and to identify catalytic molecule of
industrial=20
importance."...  [What he is suggesting is that we don't study at a=20
spirochete that causes a disease and why, but rather one that does NOT=20
cause disease because it may have commercial value.]
http://164.195.100.11/netacgi/nph-Parser?Sect1=3DPTO2&Sect2=3DHITOFF&p=3D1&=
u=3D%2Fnetahtml%2Fsearch-bool.html&r=3D0&f=3DS&l=3D50&TERM1=3D%22Barbour%2C=
+Alan%22&FIELD1=3D&co1=3DAND&TERM2=3D
&FIELD2=3D&d=3Dpall
PAT. NO.    Title  =20
1-5,846,946 Compositions and methods for administering Borrelia DNA  =20
2-5,777,095 Osp A and B Sequence of Borrelia burgdonferi strains ACA1
and IP90=20
3-5,688,512 Borrelia antigen=20
4-5,585,102 Flagella-less borrelia=20
5-5,582,990 DNA encoding borrelia burgdorferi OspA and a method for
diagnosing borrelia burgdorferi infection=20
6-5,571,718 Cloning and expression of soluble truncated variants of
Borrelia OspA, OspB and Vmp7=20
7-5,523,089 Borrelia antigen=20
8-5,436,000 Flagella-less borrelia=20
9-5,246,844 Virulence associated proteins in Borrelia burgdorferi (BB)=20
10-5,932,220   Diagnostic tests for a new spirochete, Borrelia lonestari
spp.
------------The Patents of EROL FIKRIG - Yale --------------
http://164.195.100.11/netacgi/nph-Parser?Sect1=3DPTO2&Sect2=3DHITOFF&p=3D1&=
u=3D%2Fnetahtml%2Fsearch-bool.html&r=3D0&f=3DS&l=3D50&TERM1=3D%22Fikrig%2C+=
Erol%22&FIELD1=3D&co1=3DAND&TERM2=3D&
FIELD2=3D&d=3Dpall
PAT. NO.   Title
1- 5,807,685 OspE, OspF, and S1 polypeptides in Borrelia burgdorferi=20
2- 5,747,294 Compositions and methods for the prevention and diagnosis
of Lyme disease=20
3- 5,656,451 OspE, OspF, and S1 polypeptides in borrelia burgdorferi=20
4- 5,618,533 Flagellin-based polypeptides for the diagnosis of lyme
disease=20
-------The Endeavors of RAY DATTWYLER and BEN LUFT, SUNY Stony Brook
researchers who OWN **BROOK BIOTECHNOLOGIES**.=20
Patent Applications of Ben Luft, SUNY, Stony Brook.
1)LUFT,DR. BENJAMIN J. Spon: NI Allergy + Infectious Diseases  =20
 From: 19980901  To: 19990831  Direct:    311446=20
Indirect:           88834
VACCINE INTERVENTION FOR LYME BORRELIOSIS
2)LUFT,DR. BENJAMIN    S pon: National Institutes of Health     =20
From: 19990701  To: 20000630  Direct:  111148=20
Indirect:           40902
VACCINE INTERVENTION FOR LYME BORRELIOSIS=20

NIH Grants Fiscal Year 1997 for Dattwyler and Luft's Company
http://silk.nih.gov/silk/brownbooks/sbir/org/fy97 =20
1)NEW YORK  BROOK BIOTECHNOLOGIES, INC. #  1   $324,790=20
Fiscal year 1995 http://silk.nih.gov/silk/brownbooks/sbir/org/fy95
2)NEW YORK  BROOK BIOTECHNOLOGIES, INC. # 1-$99,840
-----Funding for Raymond Dattwyler:
http://fundedresearch.cos.com/cgi-bin/NIH/getRec?P01NS340929002=20
Principal Investigator  and Address:  DATTWYLER, RAYMOND J
SUNY @ STONY BROOK    HEALTH SCIENCES CENTER, T12-02
STONY BROOK, NY 11794-8121=20
Initial Review Group:     ZNS  Performing  Organization:
STATE UNIVERSITY NEW YORK STONY BROOK=20
Grant Title: NEUROLOGIC ASPECTS OF LYME DISEASE IN NORTH AMERICA=20
Grant Expires in:  2 Year(s)=20
-----Grants that went to Luft:
http://fundedresearch.cos.com/cgi-bin/NIH/getRec?M01RR107100015
http://fundedresearch.cos.com/cgi-bin/NIH/getRec?R01AI37256
-----Funding received by Brook Biotechnologies in 1997
http://www.sba.gov/gopher/Innovation-And-Research/Awd97/awdny.txt
29146  HHS Brook Biotechnologies, Inc.         ***  $633,237 ***
Long Island High Tech Incubato 25 East Loo     Phase: 2
  Stony Brook        NY 11790-335   Minority: Woman: =20
Topic: Recombinant Based Elisa--Diagnosis of Lyme Borreliosis     =20
------Patents Pending for Ben Luft
http://www.research.sunysb.edu/research/data/pendaps.txt
1)  LUFT,DR. BENJAMIN J. Spon: National Institutes of Health     =20
From: 19981201  To: 19991130  Direct:      229409=20
Indirect:           90724
GENETIC IDENTIFICATION AND DELINEATION OF HUMAN=20
PATHOGENIC CLONES OF BORELIA BURGDORFERI
2) LUFT,DR. BENJAMIN J. Spon: NI Allergy + Infectious Diseases  =20
 From: 19980901  To: 19990831  Direct:    311446=20
Indirect:           88834
VACCINE INTERVENTION FOR LYME BORRELIOSIS
3) LUFT,DR. BENJAMIN  Spon: National Institutes of Health     =20
 From: 19990701  To: 20000630  Direct:  111148=20
Indirect: 40902 VACCINE INTERVENTION FOR LYME BORRELIOSIS=20
-------------------------------------------------
  Molecular Mimicry, the battle cry of some of these UBRs, is the=20
concept that antibodies or the immune response against Borrelia=20
burgdorferi also fit a niche on host cells.  This means that by=20
exposure to Bb, the human victim starts generating antibodies=20
against its own tissue and an inflammatory process evolves.
There is as yet no solid proof of molecular mimicry in Lyme disease. =20
   Lyme disease is a persistent spirochetal infection.  There is no=20
proof that one ever gets rid of any spirochetal infection.  Whole=20
spirochetes and spirochetal DNA have been found in the brains of=20
patients who died of Alzheimer's disease at autopsy versus none=20
in the brains of age-related patients who did not die of Alzheimer's.
   Nuns don't get Alzheimer's.  Many think it's because Alzheimer's
is a syphilitic infection that manifests as the immune system
loses integrity as we age.  It also runs along familiar lines=20
(somewhat) because one inherits one's Immune Potential:=20

***Everyone*** should be terrified of Spirochetal Diseases.

"Alzheimer's disease--a spirochetosis?  Miklossy J =20
Division of Neuropathology, University of Lausanne, Switzerland.=20
   The aetiology of Alzheimer's disease (AD), which affects a large=20
proportion of the aged population is unknown and the treatment=20
unresolved. The role of beta amyloid protein (beta A4), derived=20
from a larger amyloid precursor protein (APP) in AD is the subject=20
of intense research. Here I report observations that in 14 autopsy=20
cases with histopathologically confirmed AD, spirochetes were found=20
in blood and cerebrospinal fluid and, moreover, could be isolated=20
from brain tissue. Thirteen age-matched control cases were without
spirochetes. Reference strains of spirochetes and those isolated
from brains of AD patients, showed positive immunoreaction with=20
monoclonal antibody against the beta amyloid precursor protein.=20
These observations suggest that spirochetes may be one of the=20
causes of AD and that they may be the source of the beta amyloid=20
deposited in the AD brain."=20
--------
"Further ultrastructural evidence that spirochaetes may play a role=20
in the aetiology of Alzheimer's disease.
Miklossy J, Kasas S, Janzer RC, Ardizzoni F, Van der Loos H
Neuroreport 1994 Jun 2 5:10 1201-4
ABSTRACT --Recently it was reported that, at autopsy, in neuropath-
ologically confirmed cases of Alzheimer's disease spirochaetes were=20
found in blood and cerebrospinal fluid using dark-field  microscopy.=20
Moreover, the spirochaetes were isolated and cultured from brain=20
tissue. We now show, using scanning electron microscopy and atomic=20
force microscopy that the helically  shaped microorganisms isolated=20
and cultured from the Alzheimer brains possess axial filaments.=20
This indicates that these microorganisms taxonomically indeed=20
belong to the order Spirochaetales. A morphometric analysis=20
reinforces this notion."
---------------------------
"Borrelia rhombencephalomyelopathy.
Kuntzer T, Bogousslavsky J, Miklossy J, Steck AJ, Janzer R, Regli F
Arch Neurol 1991 Aug 48:8 832-6
ABSTRACT: Three patients, in whom the diagnosis of Borrelia=20
burgdorferi infection was unknown for several years, developed a=20
biphasic involvement of the central nervous system: an acute brain-
stem dysfunction was followed up, in two patients, by a progressive,=20
disabling myelitis and, in one patient, by further relapsing-remitting=20
episodes of severe multifocal rhombencephalitis. The most consistent=20
cerebrospinal fluid abnormalities in the analysis of sequential=20
specimens were elevated total IgM levels that normalized after=20
penicillin therapy.
 The neuropathologic findings in one patient showed microgliosis and=20
meningovascular involvement of the central nervous system, resulting=20
in two ischemic infarcts in the myelencephalon. Few spirochetes were=20
localized in the leptomeninges and around subependymal vessels of the=20
fourth ventricle. The vascular element consisted of an obliterative
inflammatory vasculopathy in the medullary parenchyma. This study=20
(1) provides pathologic evidence that a vascular disease induced by=20
B burgdorferi is a pathogenetic mechanism for  cerebrovascular=20
diseases, and (2) emphasizes the similarities between neuroborreliosis=20
and neurosyphilis."
-----------------------------------------------------------
"Meningovascular form of neuroborreliosis: similarities between=20
neuropathological findings in a case of Lyme disease and
those occurring in tertiary neurosyphilis.
  Miklossy J, Kuntzer T, Bogousslavsky J, Regli F, Janzer RC
  Acta Neuropathol (Berl) 1990 80:5 568-72
ABSTRACT:  Recent observations have delineated the neurological=20
manifestations of Lyme disease, but, to our knowledge, no detailed=20
neuropathological study from autopsy cases has been reported. In =20
this report we describe the neuropathological findings in a case of=20
Lyme neuroborreliosis. The chronic meningitis, the occlusive=20
meningovascular and secondary parenchymal changes that we found=20
are similar to those occurring in the meningovascure inforces this=20
notion."
---------------------------------------
Failed Attempts to Show Demonstrate Molecular mimicry by the UBRs:
(Article I of II:)   Cell Immunol 1999 May 25;194(1):118-23=20
"Cross-reactivity of Borrelia burgdorferi and myelin basic
protein-specific T cells is not observed in borrelial encephalomyelitis.
  Pohl-Koppe A, Logigian EL, Steere AC, Hafler DA
Center for Neurologic Diseases, Brigham and Women's Hospital, Boston,
Massachusetts, 02115, USA. Annette.P...@kk-i.med.uni-muenchen.de=20
  "Borrelial encephalomyelitis, a rare manifestation of Lyme
borreliosis,
may present as a multiple sclerosis (MS)-like disease.  It is postulated=20
that in MS, inflammation of the white matter is caused by a=20
T-cell response directed to myelin antigens.  Here, we examined=20
whether a T-cell autoimmune response may play a pathogenetic
role in Borrelia-associated white matter disease mediated by
cross-reactivity between myelin basic protein (MBP) and B.=20
burgdorferi.  We generated a total of 1760 short-term T-cell =20
lines against B. burgdorferi or MBP from two patients with=20
Borrelial encephalomyelitis and compared these with three =20
patients with late Lyme disease, one patient with transverse=20
myelitis, eight patients with MS, and four healthy controls.=20
While a few T-cell lines recognized both B. burgdorferi and=20
MBP, T-cell clones from these lines responded only to the=20
antigen of the original stimulation. Thus, our data do **not**=20
provide evidence for cross-reactivity between MBP and B.=20
burgdorferi. Copyright 1999 Academic Press."=20
___________________________________________________-
(Article II of II:)  Science 1998 Jul 31;281(5377):703-6 =20
 "Identification of LFA-1 as a candidate autoantigen in
treatment-resistant Lyme arthritis.
    Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA,=20
Field JA, Steere AC, Huber BT
Department of Pathology, Tufts University, Boston, MA 02111 USA.=20
  Treatment-resistant Lyme arthritis is associated with immune
reactivity to outer surface protein A (OspA) of Borrelia burgdorferi,
the agent=20
of Lyme disease, and the major histocompatibility complex class II=20
allele DRB1*0401. The immunodominant epitope of OspA for T helper cells
was identified. A homology search revealed a peptide from human
leukocyte function-associated antigen-1 (hLFA-1) as a candidate
autoantigen. Individuals with treatment-resistant Lyme arthritis,=20
but not other forms of arthritis, generated responses to OspA,
hLFA-1, and their highly related peptide epitopes. Identification of the
initiating bacterial antigen and a cross-reactive autoantigen *may*
provide a model for development of autoimmune disease."=20
----
There is no evidence yet that Lyme disease becomes an auto-immune=20
disease, only more and more evidence that autoimmune diseases often=20
have an infectious origin. If these UBRs can change the surveillance=20
numbers by claiming that Lyme becomes an autoimmune disease, funding
for these Rheumo/autoimmune researchers will continue to exceed=20
that for curing Lyme as an infectious disease.  They are abusing=20
the funding by developing test kits of commercial value and changing=20
their statements about the reliability of such testing, now that=20
they have a product to market from tehir private companies.
_____________________________________
More About Where Steere=92s Endeavor Lead Him:
https://www-commons.cit.nih.gov/crisp/
Grant Number: 5R03TW00514-03PI=20
Name: STEERE, ALLEN C.PI Title: Project=20
Title: LYME BORRELIOSIS IN RUSSIA=20
Abstract: DESCRIPTION (adapted from investigator's abstract): The
specific aims of the parent grant are to describe the clinical=20
manifestations of Lyme Disease in patients in New England, to=20
develop specific diagnostic tests, and to determine appropriate=20
treatment regimens for the illness. Since 1986, Dr. Steere, the
Principal Investigator of the parent grant, has participated in a
cooperative exchange with physicians at the Rheumatology Institute=20
in Moscow under the auspices of the U.S.-U.S.S.R. Biological=20
Health Agreement. It is now known that a considerable portion
of the worldwide nosoarea of Lyme borreliosis is situated within
the former Soviet Union. The infection there may be caused by any of the
three currently identified groups of the B. burgdorferi sensu latu
complex, including B. burgdorferi sensu stricto, B. garinii, and B.
afzelii.
  However, the characteristics of the disease, particularly the late
manifestations of the illness, are incompletely described in Russia,=20
and for the most part, accurate diagnostic testing is not yet available
there. In the proposed study, the clinical manifestations of Lyme
borreliosis in Russian patients will be described based on a referral=20
network of patients seen at the Rheumatology and Neurology Institutes in
Moscow, and patients seen at the Lyme Disease Center at Ekaterinburg, a
highly endemic area in the Ural Mountains, about 1,000 miles east of=20
Moscow.=20
  A Lyme disease diagnostic laboratory will be developed in=20
Moscow, and sensitive and specific diagnostic criteria for ELISA
and Western blotting tests will be developed, based on Russian case and
control subjects. Skin biopsy samples of erythema migrans skin lesions=20
will be cultured, and joint fluid and cerebrospinal fluid samples will=20
be tested by PCR in an effort to identify the groups of the B.
borrelia burgdorferi sensu latu complex which cause this infection in
Russia. Finally, the clinical data will be correlated with the=20
laboratory information in an attempt to determine whether particular=20
spirochetal groups cause different clinical pictures with different
serologic responses in Russia. These studies are important both to
understand variations of this infection in different parts of the=20
world and to aid in the diagnosis and treatment of Russian patients=20
with this curableinfection.=20
 Institution: NEW ENGLAND MEDICAL CENTER
750 WASHINGTON ST  BOSTON, MA 02111
Fiscal Year: 1997   Department: Project Start: 30-SEP-95
Project End:   29-SEP-99
ICD: FOGARTY INTERNATIONAL CENTER  IRG: ICP=20
____________________________________________
Did the Russians have to purchase an agreement to license=20
Steere=92s methods?  Lyme disease is not always a "cureable infection=94
at this point in time, or he others like him would not be getting=20
millions of dollars in grant money to study it.
____________________________________________
=20
Before Lyme disease was a Rich Vein of Gold from
which to mine diagnostic and vaccine biomolecules of commercial/
industrial value, Ray Dattwyler and SUNY had this to say about
testing for Lyme disease:=20
  "Seronegative Lyme disease. Dissociation of specific T- and
B-lymphocyte responses to Borrelia burgdorferi    [see comments]
 ***Dattwyler RJ***, Volkman DJ, Luft BJ, Halperin JJ, Thomas J,
Golightly MG  N Engl J Med 1988 Dec 1 319:22 1441-6
ABSTRACT:  The diagnosis of Lyme disease often depends on the
measurement=20
of serum antibodies to Borrelia burgdorferi, the spirochete that causes=20
this disorder. Although prompt treatment with antibiotics may
abrogate the antibody response to the infection, symptoms persist in=20
some patients. We studied 17 patientsvwho had presented with acute=20
Lyme disease and received prompt treatment with oral antibiotics, but in
whom chronic Lyme disease subsequently developed. Although these=20
patients had clinically active disease, none had diagnostic levels=20
of antibodies to B. burgdorferi on  either a standard enzyme-linked
immunosorbent assay or immunofluorescence assay. On Western blot=20
analysis, the level of immunoglobulin reactivity against B. burgdorferi=20
in serum from these patients was no greater than that in serum from
normal controls. The patients had a vigorous T-cell proliferative=20
response to whole B. burgdorferi, with a mean ( +/- SEM) stimulation=20
index of 17.8 +/- 3.3, similar to that (15.8 +/- 3.2) in 18 patients=20
with chronic Lyme disease who had detectable antibodies. The T-cell=20
response of both groups was greater than that of a control group of=20
healthy subjects (3.1 +/- 0.5; P less than 0.001).=20
  We conclude that the presence of chronic Lyme disease cannot be=20
excluded by the absence of antibodies against B. burgdorferi and=20
that a specific T-cell blastogenic response to B. burgdorferi is=20
evidence of infection in seronegative patients  with clinical
indications of chronic Lyme disease."

NOW Dattwyler has this to say:
  Chembio Takes Lead In Rapid-Test Race / First to get FDA=20
  OK online disease kit    By Michael Unger. STAFF WRITER=20
Biotechnology executive Tom Haendler says he knew he was in the right =20
business when even the monster movie he watched on a TransAtlantic jet=20
portrayed home pregnancy tests like the one his Long Island company
manufactures. While watching "Godzilla" as he returned from a
medical technology show in Europe last year, the picture's hero goes=20
into a drugstore and buys over-the-counter home pregnancy tests to=20
determine whether the monster terrorizing New York City is pregnant.=20
Said Haendler, president of Chembio Diagnostics Systems, "If this=20
[pregnancy test] made the movie, then I'm sure we're on the right
track."=20
    Now, privately held Chembio of Medford, in its latest venture into
the  rapidly growing diagnostic-test industry, has a deal with a large=20
pharmaceutical company in New Jersey, Carter Wallace, to market the
first rapid Lyme disease test.=20
    The worldwide market for rapid diagnostic tests for both home and=20
professional use is far more than $2 billion, analysts say. And while=20
it is far from being alone in the market of fast tests,Chembio has made=20
rapid biotech pregnancy test kits for both the home market and doctors'=20
offices, hospitals and clinics for several years. Now it has taken the=20
lead in quick tests for Lyme disease.=20
     The company, formed with venture capital investors headed by=20
company chairman Lawrence Siebert, has developed numerous other rapid=20
tests for tuberculosis, ulcers and newly emerging diseases and parasites=20
now sometimes found in the United States, such as malaria, Chaga's
disease and Dengue Fever.=20
   Just last week, Chembio became the first company to win the U.S.
Food and Drug Administration's approval to market a simple test to show
whether someone has been bitten by a tick infected with Lyme disease. =20
The test shows positive or negative for the presence of antibody
markers  for the Lyme organism within 20 minutes. It also gives doctors=20
a signal  whether to start crucial antibiotic treatment immediately=20
instead of potential delays at an outside laboratory. Even so, the=20
FDA recommends that positive Lyme results on the Chembio rapid blood=20
test be confirmed with a second test at a clinical laboratory.=20
    For the moment, Chembio is alone in the field with its Lyme test; =20
but other companies are hot on the trail.  Chembio's Lyme test is better=20
than 95 percent accurate, according to clinical tests, and is the first=20
rapid Lyme test to pass FDA muster. It will be marketed starting in
April, Chembio says, for doctors' offices, hospitals, clinics and=20
reference laboratories. An over-the-counter version for consumers'=20
home use is in the works. The price has not been determined.   =20
The test uses technology developed by Lyme disease experts at the
State University at Stony Brook medical school and Brookhaven National=20
Laboratory. It was developed jointly by Chembio and by Brook
Biotechnologies Inc. in the Long Island High Technology Incubator in
Stony Brook.=20
    "That's our test," said Dr. Raymond J. Dattwyler, president of
Brook  Biotechnologies who also heads the Lyme Disease Center at the
State University at Stony Brook's Health Sciences Center. Dattwyler and
Dr. Benjamin J. Luft, chairman of medicine at Stony Brook, are the
inventors, along with Dr. John Dunn of the Brookhaven National
Laboratory Biology Department. The patents are owned by the State=20
University and Brookhaven National Laboratory.=20
    At the Chembio plant on Horseblock Road, several dozen women in
blue pharmaceutical garb assemble the various kinds of test kits by=20
hand. The company's platform technology requires only a drop of blood,=20
urine or mucous on a treated membrane strip to show negative or positive
results.  Chembio scientists Sat Nam S. Hanjan, Mewa Singh and Hema Mana=20
explain that the biochemical reactions begin to appear on the small
plastic indicators within a minute or two and usually take no more=20
than 15 or 20 minutes to fully develop and complete. The kits are=20
manufactured in the Medford plant in batches of 10,000 to 100,000.=20
   "We're hoping that many of these tests eventually will be available=20
for consumer purchase for use at home," Hanjan said. Chembio recently=20
won a $100,000 research grant from the federal government to develop a=20
rapid biotech test for new strains of drug-resistant tuberculosis. A
rapid AIDS test also is in the works.=20
   The company believes it is on the leading edge of the trend toward=20
ultra-fast testing. "It's the way everything is going to go," says Avi=20
Pelossof, Chembio's marketing director. "It's a great industry to
be in," said Haendler. "And we're in it at the right time." "

We patients contend that these UBRS are not spending his time trying
to discover what works in terms of treatment for Lyme disease by=20
virtue of the time they must be spending at SUNY, ChemBio and Brook=20
Biotechnologies developing Test Kits.  They changed their tune about=20
the adequacy of serology in diagnosis (95%) when they had a test
kit to sell.=20
--------------
Endeavors of Allen Steere:
Internal letter from a company in CT:
"Sent: Friday, July 02, 1999 2:59 PM
 Subject: CDC Lyme Disease Study
"....Dr. Allen Steere will be=20
working on a CDC and NIH supported Lyme Disease study for which=20
they are seeking patient volunteers.  This study has been approved by
Tufts/New England Medical Center's Institutional Review Board.
They are primarily interested in patients with physician diagnosed
erythema migrans, in whom they will be studying pathogenesis of=20
disease, histopathology, molecular and genetic diversity of Borrelia
burgdorferi isolates, cell-mediated immune factors, and serology, in the
setting of clinical presentation. These patients will have skin=20
biopsy of the lesion (small enough to be dressed with a
bandaid, no sutures) as well as bloodwork on the day of presentation.
Lyme disease treatment will be initiated at that time. Only one
follow-up visit is required for convalescent bloodwork, 2 to 4 weeks
later. The grant provides for a $100 payment to these volunteers..."

Patients with Chronic Lyme disease contend that if Dr. Steere was truly
interested in the relative virulence, he would ask the patients to come=20
back at 6 months, 1 year, 2 years, etc., to see which strains have
the worst remaining effect on the patient.

Steere is looking for new strains.  If he finds one, he
can patent it, like the rest of the people who are making money
off of Lyme disease.

   Imugen, a lab in Norwood, MA, is in a partnership with CORIXA =20
another growing biotech company...Here's why:=20
http://www.corixa.com/parpro/partnered.asp
Target Product:   Reference diagnostic for detection of certain
tick-borne diseases    Status: Development
Partner:  IMUGEN, Inc.
    Corixa and others are looking for markers of infection; to patent=20
other commercially viable diagnostic test kit antibodies/ biomolecules.
-------------------------------------------------------
From a Corixa Press release,  April 7, 1998...
"...The agreement provides Imugen with an exclusive license,=20
including the right to sub-license these recombinant antigens =20
for reference laboratory testing in the US and Canada
in exchange for a share of revenues from any diagnostics
kits or blood screening tests that are developed as a=20
result of this collaboration..."
---------------------------------------------------------
We are tired of all this greed and intrigue. We're sick, so=20
we're not even good candidates for vaccines... These people,=20
Steere, Barbour, Dattwyler, Luft, Fikrig, etc., biopsy our=20
rashes so thay can make money on a new antigen (vaccines) or
identify new antibodies to identify by test kit. =20

Meanwhile, we Lyme Patients and the doctors that help us=20
try to keep the infection under control until a cure is found,
are the worthless by-products of their endeavors. =20

We don't want them funded by the US Government any longer.  Since=20
many now have their own independent research facilities, patents and=20
patents pending, they are financially capable of continuing =20
research without US Govt Grants.

We want the majority of future funding for Lyme disease
to be focused upon requests for grants to study treatment
modalities and related science.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s